tetano
Editor, Senior Moderator
Mol Cell
. 2020 Aug 4;S1097-2765(20)30518-9.
doi: 10.1016/j.molcel.2020.07.027. Online ahead of print.
Coronavirus RNA Proofreading: Molecular Basis and Therapeutic Targeting
Fran Robson[SUP] 1 [/SUP], Khadija Shahed Khan[SUP] 2 [/SUP], Thi Khanh Le[SUP] 3 [/SUP], Cl?ment Paris[SUP] 4 [/SUP], Sinem Demirbag[SUP] 5 [/SUP], Peter Barfuss[SUP] 6 [/SUP], Palma Rocchi[SUP] 4 [/SUP], Wai-Lung Ng[SUP] 7 [/SUP]
Affiliations
Abstract
The coronavirus disease 2019 (COVID-19) that is wreaking havoc on worldwide public health and economies has heightened awareness about the lack of effective antiviral treatments for human coronaviruses (CoVs). Many current antivirals, notably nucleoside analogs (NAs), exert their effect by incorporation into viral genomes and subsequent disruption of viral replication and fidelity. The development of anti-CoV drugs has long been hindered by the capacity of CoVs to proofread and remove mismatched nucleotides during genome replication and transcription. Here, we review the molecular basis of the CoV proofreading complex and evaluate its potential as a drug target. We also consider existing nucleoside analogs and novel genomic techniques as potential anti-CoV therapeutics that could be used individually or in combination to target the proofreading mechanism.
Keywords: ASO; CoV; ExoN; NA; anti-coronavirus drugs; antisense oligonucleotide; coronavirus; exonuclease; non-structural protein 14; nsp14; nucleoside analog.
. 2020 Aug 4;S1097-2765(20)30518-9.
doi: 10.1016/j.molcel.2020.07.027. Online ahead of print.
Coronavirus RNA Proofreading: Molecular Basis and Therapeutic Targeting
Fran Robson[SUP] 1 [/SUP], Khadija Shahed Khan[SUP] 2 [/SUP], Thi Khanh Le[SUP] 3 [/SUP], Cl?ment Paris[SUP] 4 [/SUP], Sinem Demirbag[SUP] 5 [/SUP], Peter Barfuss[SUP] 6 [/SUP], Palma Rocchi[SUP] 4 [/SUP], Wai-Lung Ng[SUP] 7 [/SUP]
Affiliations
- PMID: 32853546
- DOI: 10.1016/j.molcel.2020.07.027
Abstract
The coronavirus disease 2019 (COVID-19) that is wreaking havoc on worldwide public health and economies has heightened awareness about the lack of effective antiviral treatments for human coronaviruses (CoVs). Many current antivirals, notably nucleoside analogs (NAs), exert their effect by incorporation into viral genomes and subsequent disruption of viral replication and fidelity. The development of anti-CoV drugs has long been hindered by the capacity of CoVs to proofread and remove mismatched nucleotides during genome replication and transcription. Here, we review the molecular basis of the CoV proofreading complex and evaluate its potential as a drug target. We also consider existing nucleoside analogs and novel genomic techniques as potential anti-CoV therapeutics that could be used individually or in combination to target the proofreading mechanism.
Keywords: ASO; CoV; ExoN; NA; anti-coronavirus drugs; antisense oligonucleotide; coronavirus; exonuclease; non-structural protein 14; nsp14; nucleoside analog.